<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(2)</volume><submitter>Aziz S</submitter><pubmed_abstract>Presence of lymph node (LN) metastasis is a strong prognostic factor in breast cancer, whereas the importance of extra-nodal extension and other nodal tumor features have not yet been fully recognized. Here, we examined microscopic features of lymph node metastases and their prognostic value in a population-based cohort of node positive breast cancer (n = 218), as part of the prospective Norwegian Breast Cancer Screening Program NBCSP (1996-2009). Sections were reviewed for the largest metastatic tumor diameter (TD-MET), nodal afferent and efferent vascular invasion (AVI and EVI), extra-nodal extension (ENE), number of ENE foci, as well as circumferential (CD-ENE) and perpendicular (PD-ENE) diameter of extra-nodal growth. Number of positive lymph nodes, EVI, and PD-ENE were significantly increased with larger primary tumor (PT) diameter. Univariate survival analysis showed that several features of nodal metastases were associated with disease-free (DFS) or breast cancer specific survival (BCSS). Multivariate analysis demonstrated an independent prognostic value of PD-ENE (with 3 mm as cut-off value) in predicting DFS and BCSS, along with number of positive nodes and histologic grade of the primary tumor (for DFS: P = 0.01, P = 0.02, P = 0.01, respectively; for BCSS: P = 0.02, P = 0.008, P = 0.02, respectively). To conclude, the extent of ENE by its perpendicular diameter was independently prognostic and should be considered in line with nodal tumor burden in treatment decisions of node positive breast cancer.</pubmed_abstract><journal>PloS one</journal><pagination>e0171853</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5310784</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer.</pubmed_title><pmcid>PMC5310784</pmcid><pubmed_authors>Klingen TA</pubmed_authors><pubmed_authors>Wik E</pubmed_authors><pubmed_authors>Aas T</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Aas H</pubmed_authors><pubmed_authors>Knutsvik G</pubmed_authors><pubmed_authors>Davidsen B</pubmed_authors><pubmed_authors>Aziz S</pubmed_authors><pubmed_authors>Akslen LA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer.</name><description>Presence of lymph node (LN) metastasis is a strong prognostic factor in breast cancer, whereas the importance of extra-nodal extension and other nodal tumor features have not yet been fully recognized. Here, we examined microscopic features of lymph node metastases and their prognostic value in a population-based cohort of node positive breast cancer (n = 218), as part of the prospective Norwegian Breast Cancer Screening Program NBCSP (1996-2009). Sections were reviewed for the largest metastatic tumor diameter (TD-MET), nodal afferent and efferent vascular invasion (AVI and EVI), extra-nodal extension (ENE), number of ENE foci, as well as circumferential (CD-ENE) and perpendicular (PD-ENE) diameter of extra-nodal growth. Number of positive lymph nodes, EVI, and PD-ENE were significantly increased with larger primary tumor (PT) diameter. Univariate survival analysis showed that several features of nodal metastases were associated with disease-free (DFS) or breast cancer specific survival (BCSS). Multivariate analysis demonstrated an independent prognostic value of PD-ENE (with 3 mm as cut-off value) in predicting DFS and BCSS, along with number of positive nodes and histologic grade of the primary tumor (for DFS: P = 0.01, P = 0.02, P = 0.01, respectively; for BCSS: P = 0.02, P = 0.008, P = 0.02, respectively). To conclude, the extent of ENE by its perpendicular diameter was independently prognostic and should be considered in line with nodal tumor burden in treatment decisions of node positive breast cancer.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017</publication><modification>2021-02-20T13:16:35Z</modification><creation>2019-03-26T22:49:13Z</creation></dates><accession>S-EPMC5310784</accession><cross_references><pubmed>28199370</pubmed><doi>10.1371/journal.pone.0171853</doi></cross_references></HashMap>